Seladelpar
Brand names: Livdelzi Β· Active ingredient: Seladelpar Lysine
In short: LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a
What is Seladelpar used for?
LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP) . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use
Use of LIVDELZI is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy) .
Seladelpar dosage
The recommended dosage of LIVDELZI is 10 mg orally once daily. Administer LIVDELZI with or without food .
Administer LIVDELZI at least 4 hours before or 4 hours after taking bile acid sequestrants, or at as great an interval as possible .
How to take Seladelpar β instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Fractures
Inform patients that LIVDELZI may increase the risk of bone fractures. Advise patients to call their healthcare provider to report any fractures .
Liver Test Abnormalities
Instruct patients to report any signs or symptoms of liver-related adverse reactions (e.g., loss of appetite, nausea, increased fatigue, lower extremity edema, abdominal swelling, or jaundice/icterus) to their healthcare provider .
Biliary Obstruction
Instruct patients to immediately report any signs or symptoms of biliary obstruction (e.g., right upper quadrant pain, jaundice) to their healthcare provider so that LIVDELZI treatment can be interrupted while the patient is being evaluated .
Pregnancy
Advise patients that there is a pregnancy safety study that captures pregnancy outcomes in women exposed to LIVDELZI during pregnancy, and to report pregnancies and pregnancy outcomes by calling 1-800-445-3235 .
Warnings & precautions
Do not take this medicine if: None.
Fractures occurred in 4% of LIVDELZI-treated patients compared to no placebo-treated patients .
Consider the risk of fracture in the care of patients treated with LIVDELZI and monitor bone health according to current standards of care.
LIVDELZI has been associated with dose-related increases in serum transaminase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels greater than 3-times upper limit of normal (ULN) in PBC patients receiving 50 mg once daily (5-times higher than the recommended dosage) and 200 mg (20-times higher than the recommended dosage) once daily. Transaminase levels returned to pretreatment levels upon LIVDELZI discontinuation. LIVDELZI 10 mg once daily did not show a similar pattern for increases in transaminase levels .
Obtain baseline clinical and laboratory assessments at treatment initiation with LIVDELZI and monitor thereafter according to routine patient management. Interrupt LIVDELZI treatment if the liver tests (ALT, AST, total bilirubin [TB], and/or alkaline phosphatase [ALP]) worsen, or the patient develops signs and symptoms consistent with clinical hepatitis (e.g., jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting LIVDELZI.
Avoid use of LIVDELZI in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LIVDELZI and treat as clinically indicated.
Seladelpar side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Fractures
Liver Test Abnormalities
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In Trial 1, 193 patients were randomized to receive either LIVDELZI 10 mg (N=128) or placebo (N=65) once daily for 12 months . LIVDELZI or placebo was administered in combination with UDCA in 94% of patients and as monotherapy in 6% of patients who were unable to tolerate UDCA.
Common Adverse Reactions
Table 1 presents common adverse reactions that occurred in Trial 1.
Adverse ReactionOccurring in greater than or equal to 5% of patients in the LIVDELZI treatment arm and at an incidence greater than or equal to 1% higher than in the placebo arm. | LIVDELZI 10 mg Once Daily (N=128) % (n) | PLACEBO (N=65) % (n)
Headache | 8% (10) | 3% (2)
Abdominal painThe gastrointestinal adverse reactions were mild to moderate without the need for discontinuation of LIVDELZI. | 7% (9) | 2% (1)
Nausea | 6% (8) | 5% (3)
Abdominal distension | 6% (8) | 3% (2)
Dizziness | 5% (6) | 2% (1)
Fractures
In Trial 1, fractures occurred in 4% (n=5) of LIVDELZI-treated patients compared to no placebo-treated patients. Baseline bone mineral density was not obtained. β¦
Drug interactions
Table 2 includes clinically significant drug interactions affecting LIVDELZI.
Concomitant Drug or Class | Potential Effect on Seladelpar Exposureβ = Increase, β = Decrease. | Clinical Intervention
Probenecid | β seladelpar | Avoid concomitant administration of LIVDELZI with probenecid.
Strong CYP2C9 Inhibitors | β seladelpar | Monitor patients for adverse effects during concomitant use of LIVDELZI with strong CYP2C9 inhibitors.
Dual Moderate CYP2C9 and Moderate or Strong CYP3A4 Inhibitors (e.g., fluconazole) | β seladelpar | Monitor patients for adverse effects during concomitant use of LIVDELZI with drugs that are dual moderate CYP2C9 and moderate or strong CYP3A4 inhibitors.
CYP2C9 Poor Metabolizers Using Moderate or Strong CYP3A4 Inhibitors | β seladelpar | Monitor patients who are CYP2C9 poor metabolizers for adverse effects during concomitant use of LIVDELZI with moderate or strong CYP3A4 inhibitor.
Dual or Multiple Clinical Inhibitors of Drug Transporters OATP1B1, OATP1B3, and BCRP (e.g, cyclosporine) | β seladelpar | Monitor patients for adverse effects during concomitant use of LIVDELZI with dual or multiple clinical inhibitors of drug transporters OATP1B1, OATP1B3, and BCRP. β¦
About this medicine
LIVDELZI capsules contain seladelpar lysine, a peroxisome proliferator-activated receptor (PPAR)-delta (Ξ΄) agonist. Seladelpar is a single enantiomer of the R-configuration and is present as a lysine dihydrate salt. Seladelpar lysine dihydrate is a white to off-white powder with a molecular formula of C21H23F3O5S βC6H14N2O2 β2H2O and a molecular weight of 626.7 g/mol. Its solubility in water is pH dependent. It is slightly soluble at low pH and very soluble at high pH. The chemical name for seladelpar lysine dihydrate is 2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid, lysine dihydrate, and the chemical structure is:
LIVDELZI (seladelpar) capsules are supplied in a 10 mg strength for oral administration. Each capsule contains 14.1 mg of seladelpar lysine and the following inactive ingredients: butylated hydroxytoluene, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and hard gelatin shells. β¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 89f79d98-135c-40b2-a585-6996c04e599c. Read the full official label on DailyMed.